CORD-19:c654596857bce9cdd64ffc51842048643107348c / 70210-70346 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/c654596857bce9cdd64ffc51842048643107348c","sourcedb":"CORD-19","sourceid":"c654596857bce9cdd64ffc51842048643107348c","text":"41.1% for 85B and 70.5% for ESAT-6 of the patients tested were responders in ELISPOT-assay versus 57.9% for both in proliferation assay.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T564","span":{"begin":0,"end":136},"obj":"Sentence"},{"id":"T19567","span":{"begin":0,"end":136},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T564","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T19567","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T160","span":{"begin":0,"end":136},"obj":"Sentence"}],"attributes":[{"subj":"T160","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ecc493","default":true},{"id":"CORD-19_Custom_license_subset","color":"#a993ec"}]}]}}